Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

Laura Sargentini‐Maier, Maria; De Decker, Philip; Tersteeg, Claudia; Canvin, Jan; Callewaert, Filip; De Winter, Hilde

doi:10.1080/17512433.2019.1607293

Public

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

Published in Expert Review of Clinical Pharmacology • Apr 12, 2019

Authors:

Maria Laura Sargentini‐Maier

Philip De Decker

Claudia Tersteeg

Abstract

Introduction: Caplacizumab is a humanized anti-von Willebrand Factor (vWF) Nanobody® for the treatment of acquired Thrombotic Thrombocytopenic Purpura (aTTP). Caplacizumab targets the A1-domain of vWF, inhibiting the interaction between vWF and platelets. Clinical studies conducted in aTTP patients ...

Subject

Medicine

Pharmacokinetics

Pharmacology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!